![[APHA]](/images/logo_apha.svg){kind=logo}
Australian cancer patients will have better access to advanced treatments in investigator-led clinical trials thanks to Icon Group's new partnership.
The country's leading dedicated cancer care provider has teamed up with GreenLight Clinical to speed up the design and implementation of trials focused on theranostics techniques.
Australia is recognised globally as a leader in the rapidly-expanding, personalised approach that combines highly-targeted cancer imaging with precision radiopharmaceutical therapies.
Icon's national and international clinical network and investigator leadership will combine with GreenLight Clinical's regulatory, data management, biostatistics and study startup capabilities.
"This partnership gives us the ability to shape a study's feasibility, workflow and operational requirements before the protocol is finalised," said Icon's Group Executive Manager for Research, Sophie Mepham.
"We're creating a streamlined route for global companies seeking to run high‐quality, investigator-led oncology trials in Australia and ultimately improve patient outcomes."
By engaging clinicians from the start and combining operational and clinical expertise upfront, the collaboration gives pharmaceutical and biotech company 'sponsors' a coordinated, flexible and streamlined pathway from protocol development through to first-patient recruitment.
"Global competition for high‐quality trial sites is intensifying, and inappropriate site and Principal Investigator selection can lead to project delay and failure," GreenLight Clinical CEO Dr Robert Lin said.
Dr Nat Lenzo, Icon's Clinical Director for Molecular Imaging and Nuclear Oncology (Asia Pacific)
"Sponsors need certainty that a study can start and enrol patients quickly and produce data that regulators will trust."
The rapid advancements in theranostics means clinical input into trial design is needed more than ever, said Dr Nat Lenzo – Icon's Clinical Director for Molecular Imaging and Nuclear Oncology (Asia Pacific).
"The clinical nuances matter. When clinicians are involved early, we can help ensure protocols reflect real‐world practice from imaging schedules to patient-safety considerations," he said.
"This leads to more practical study designs, fewer amendments and ultimately a smoother experience for both patients and sites."
The partnership will star by accelerating access to investigator-led theranostics trials at the new Icon Cancer Centre Hollywood in Western Australia, and complement Icon's ongoing investment in precision medicine across its global network.
Read more: International recognition for Icon specialists
Read more: 'Major milestone' for advanced cancer care in Australia
Read more: Icon partnership opens access to advanced cancer care
Next Safety And Quality:
3/5/2026 'Landmark moment' for Gold Coast hospital
Previous Safety And Quality:
19/3/2026 Australian-first centre 'future of cancer care'